News
The company’s recent multicenter review reported encouraging 6‑ and 12‑month follow‑up results from a feasibility study using the nPulse Cardiac Catheter. Preclinical work also demonstrated that nanosecond PFA generates substantially deeper tissue lesions than microsecond pulses, underscoring the technology’s therapeutic advantage.
04/02/2026 | Pulse Biosciences, Inc.
Pulse Biosciences (Nasdaq: PLSE) announced that its nPulse technology will be highlighted at the 31st Annual AF Symposium 2026, where a live case transmission will showcase the nPulse Cardiac Catheter integrated with Abbott’s EnSiteX 3D Mapping System. The live broadcast, scheduled at Na Homolce Hospital in Prague, CZ, will present data on the pote...
04/02/2026 | Pulse Biosciences, Inc.
Natural Resource Partners L.P. is a high‑quality royalty‑driven company with an expanding renewable‑energy arm. Its robust free cash flow, disciplined capex, and aggressive balance‑sheet improvement strategy position it well for future dividend growth, provided the coal‑industry risks and regulatory environment stay manageable.
04/02/2026 | Natural Resource Partners L.P.
- NRP is actively moving toward a “fortress” balance sheet, targeting $30 million of cash and zero permanent debt by the next year. The plan is to leverage this strong liquidity to potentially lift distributions, driven by durable royalty cash flows and a “free‑call” option created by unleased carbon‑sequestration pore space.
04/02/2026 | Natural Resource Partners L.P.
The partnership with Tempus is a critical enabler. Tempus provides a one‑click ordering system that accelerates deployment, while PSNL captures a fixed $9.6 M distribution fee plus additional upside through data‑licensing royalties. Projections assume that capturing 6 % of the market by 2029 would generate $100 M EBIT, implying a $2 B valuation at...
04/02/2026 | Personalis, Inc.
Personalis, Inc. (PSNL) stands out as an attractive investment opportunity thanks to its flagship NeXT Personal test, a liquid‑biopsy platform that identifies cancer recurrence 12–18 months earlier than conventional imaging. The assay employs whole‑genome sequencing to track up to 1,800 tumor variants, yielding significantly higher detection rates...
04/02/2026 | Personalis, Inc.
The rising debt load is a notable risk to long‑term financial stability, yet the firm’s stable cash flow and ability to cover its obligations suggest a degree of resilience that may cushion it against forthcoming challenges. The company’s financial profile, therefore, presents a mixed outlook: solid revenue and liquidity juxtaposed with escalating...
03/02/2026 | Frontage Holdings Corporation
Revenue generation remains robust, with the company operating across the aquaculture value chain—from production to distribution of aquatic products. Earnings have declined over the most recent year, but short‑term assets still cover both short‑ and long‑term liabilities, demonstrating balance‑sheet resilience.
03/02/2026 | Frontage Holdings Corporation
Here is a concise summary of the key metrics for the companies you’re interested in, as of the most recent financial data (up to 2024-06). I’ll include the company name, ticker, market cap, P/E ratio, dividend yield, and recent performance highlights (Q1 2026).
03/02/2026 | Burke & Herbert Financial Services Corp.
We have a conversation: the user gave a brief news headline, but not the company name. They want the article. So respond with a request: "Which company would you like to analyze?" That's all. We'll comply.Best Value Stocks to Buy for February 2, 2026
03/02/2026 | Burke & Herbert Financial Services Corp.